- Home
- CLOV vs TSHA Comparison
CLOV vs TSHA Comparison
Compare CLOV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLOV | TSHA |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLOV | TSHA |
|---|---|---|
| Price | $2.21 | $6.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $2.90 | ★ $11.11 |
| AVG Volume (30 Days) | ★ 5.0M | 3.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,924,308,000.00 | $9,773,000.00 |
| Revenue This Year | $52.59 | N/A |
| Revenue Next Year | $15.37 | $1,228.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.34 | 17.28 |
| 52 Week Low | $1.58 | $1.46 |
| 52 Week High | $3.92 | $6.50 |
Technical Indicators
Market Signals| Indicator | CLOV | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 71.44 | 77.02 |
| Support Level | $1.96 | $4.39 |
| Resistance Level | $2.25 | N/A |
| Average True Range (ATR) | 0.11 | 0.38 |
| MACD | 0.05 | 0.24 |
| Stochastic Oscillator | 96.27 | 90.94 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.